Paper41316355
Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature.
Chandrasekaran S and 7 others. J Med Case Rep, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature. Papers, record 41316355. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41316355
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Unraveling COVID-19-vaccination-induced bullous pemphigoid: a case report and review of the literature.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pemphigoid, Bullous | Major topic |
| COVID-19 | Major topic |
| COVID-19 Vaccines | Major topic |
| Humans | |
| Male | |
| Aged, 80 and over | |
| SARS-CoV-2 | |
| BNT162 Vaccine | |
| Vaccination | |
| Diabetes Mellitus, Type 2 |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36041291 | Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review. | J Autoimmun | 2022 | https://conductscience.org/library/papers/36041291 | PubMed |
| 2 | 36849670 | Mucous Membrane Pemphigoid Following the Administration of COVID-19 Vaccine. | Head Neck Pathol | 2023 | https://conductscience.org/library/papers/36849670 | PubMed |
| 3 | 36578130 | SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid. | J Dermatol | 2023 | https://conductscience.org/library/papers/36578130 | PubMed |
| 4 | 35141881 | SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. | Int J Dermatol | 2022 | https://conductscience.org/library/papers/35141881 | PubMed |
| 5 | 34292611 | Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. | J Cutan Pathol | 2022 | https://conductscience.org/library/papers/34292611 | PubMed |
| 6 | 34957554 | New-onset autoimmune phenomena post-COVID-19 vaccination. | Immunology | 2022 | https://conductscience.org/library/papers/34957554 | PubMed |
| 7 | 34275656 | Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. | J Allergy Clin Immunol | 2021 | https://conductscience.org/library/papers/34275656 | PubMed |
| 8 | 34928518 | Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review. | J Eur Acad Dermatol Venereol | 2022 | https://conductscience.org/library/papers/34928518 | PubMed |
| 9 | 36259862 | A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination. | Dermatol Online J | 2022 | https://conductscience.org/library/papers/36259862 | PubMed |
| 10 | 34606112 | Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy. | J Eur Acad Dermatol Venereol | 2022 | https://conductscience.org/library/papers/34606112 | PubMed |
| 11 | 34715347 | Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. | Clin Microbiol Infect | 2022 | https://conductscience.org/library/papers/34715347 | PubMed |
| 12 | 36744126 | Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine. | Front Med (Lausanne) | 2023 | https://conductscience.org/library/papers/36744126 | PubMed |
| 13 | 38099105 | COVID-19 Vaccine-Triggered Bullous Pemphigoid: Two New Cases from Saudi Arabia. | Indian J Dermatol | 2023 | https://conductscience.org/library/papers/38099105 | PubMed |
| 14 | 35073431 | Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination. | J Eur Acad Dermatol Venereol | 2022 | https://conductscience.org/library/papers/35073431 | PubMed |
| 15 | 33515320 | SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. | Rheumatol Int | 2021 | https://conductscience.org/library/papers/33515320 | PubMed |
| 16 | 35608483 | Bullous pemphigoid after inactivated COVID-19 vaccination: Case report. | Dermatol Ther | 2022 | https://conductscience.org/library/papers/35608483 | PubMed |
| 17 | 35716105 | Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. | Dermatol Ther | 2022 | https://conductscience.org/library/papers/35716105 | PubMed |
| 18 | 38483787 | Post COVID-19 vaccination medium vessel vasculitis: a systematic review of case reports. | Infection | 2024 | https://conductscience.org/library/papers/38483787 | PubMed |
| 19 | 35887732 | Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies. | J Clin Med | 2022 | https://conductscience.org/library/papers/35887732 | PubMed |
| 20 | 37406312 | New-Onset Pemphigoid Gestationis Following COVID-19 Vaccination. | Cutis | 2023 | https://conductscience.org/library/papers/37406312 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41316355
GET https://conductscience.org/api/papers/v1/41316355/references?page=2